Chugai Pharmaceutical Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Chugai Pharmaceutical Co., Ltd. – Product Pipeline Review, 2016’, provides an overview of the Chugai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.

The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Chugai Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Chugai Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Chugai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Chugai Pharmaceutical Co., Ltd. Snapshot 7

Chugai Pharmaceutical Co., Ltd. Overview 7

Key Information 7

Key Facts 7

Chugai Pharmaceutical Co., Ltd. - Research and Development Overview 8

Key Therapeutic Areas 8

Chugai Pharmaceutical Co., Ltd. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance 17

Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Chugai Pharmaceutical Co., Ltd. - Drug Profiles 22

atezolizumab 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

bevacizumab 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

eldecalcitol 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

gantenerumab 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

lebrikizumab 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

obinutuzumab 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SA-237 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

tocilizumab 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

codrituzumab 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

nemolizumab 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

basmisanil 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

EOS-789 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

PCO-371 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

polatuzumab vedotin 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

RG-7304 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

taselisib 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

CH-5036249 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

CH-5164840 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

CH-5449302 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

CH-5451098 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CVE-199 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ERY-974 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

maxacalcitol 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NA-255 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

gMSC-1 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis 74

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target 74

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 76

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 77

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 78

Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates 80

Chugai Pharmaceutical Co., Ltd. - Dormant Projects 108

Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 109

Discontinued Pipeline Product Profiles 109

nitazoxanide 109

basimglurant 109

bevacizumab 110

hyaluronate sodium 110

NA-808 111

onartuzumab 111

orlistat 111

PA-799 111

parsatuzumab 111

pictilisib 111

RG-7167 112

sembragiline 112

tocilizumab 112

trastuzumab emtansine 112

Chugai Pharmaceutical Co., Ltd. - Company Statement 113

Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries 115

Head Office 115

Other Locations & Subsidiaries 115

Appendix 118

Methodology 118

Coverage 118

Secondary Research 118

Primary Research 118

Expert Panel Validation 118

Contact Us 118

Disclaimer 119

List of Tables

List of Tables

Chugai Pharmaceutical Co., Ltd., Key Information 7

Chugai Pharmaceutical Co., Ltd., Key Facts 7

Chugai Pharmaceutical Co., Ltd. – Pipeline by Indication, 2016 9

Chugai Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 11

Chugai Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 12

Chugai Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2016 13

Chugai Pharmaceutical Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 14

Chugai Pharmaceutical Co., Ltd. – Out-Licensed Products in Pipeline, 2016 15

Chugai Pharmaceutical Co., Ltd. – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Chugai Pharmaceutical Co., Ltd. – Phase III, 2016 17

Chugai Pharmaceutical Co., Ltd. – Phase II, 2016 18

Chugai Pharmaceutical Co., Ltd. – Phase I, 2016 19

Chugai Pharmaceutical Co., Ltd. – Preclinical, 2016 20

Chugai Pharmaceutical Co., Ltd. – Discovery, 2016 21

Chugai Pharmaceutical Co., Ltd. – Pipeline by Target, 2016 74

Chugai Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 76

Chugai Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 77

Chugai Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 78

Chugai Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2016 80

Chugai Pharmaceutical Co., Ltd. – Dormant Developmental Projects,2016 108

Chugai Pharmaceutical Co., Ltd. – Discontinued Pipeline Products, 2016 109

Chugai Pharmaceutical Co., Ltd., Other Locations 115

Chugai Pharmaceutical Co., Ltd., Subsidiaries 116

List of Figures

List of Figures

Chugai Pharmaceutical Co., Ltd. – Pipeline by Top 10 Indication, 2016 9

Chugai Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2016 11

Chugai Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2016 12

Chugai Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2016 13

Chugai Pharmaceutical Co., Ltd. – Out-Licensed Products in Pipeline, 2016 15

Chugai Pharmaceutical Co., Ltd. – Pipeline by Top 10 Target, 2016 74

Chugai Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2016 76

Chugai Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2016 77

Chugai Pharmaceutical Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 78

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports